This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Opportunities to Individualize Treatment and Alter the Course of Interstitial Lung Disease—Interactive Monograph

Opportunities to Individualize Treatment and Alter the Course of Interstitial Lung Disease—Interactive Monograph


Interactive Monograph

Time to Complete

45 minutes


October 6, 2017


October 6, 2018
Add to Queue

Maximum Credits

0.75 / AMA PRA Category 1 CreditTM

Accredited Provider

Provided by Integrity Continuing Education

Commercial Supporter

Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Program Description

Interstitial lung disease (ILD) presents a unique and difficult challenge in the hospital setting due to the chronic nature of the precipitating condition. Studies have shown that elderly patients and patients in long-term care settings with ILD are significantly more likely to be hospitalized than patients without. In general, the progressive restrictive-ventilatory limitation, hypoxia, dyspnea, and cough typically observed in patients with an ILD are associated with significant quality of life (QOL) impairments and, in some cases, can result in death from respiratory failure. Therefore, there is a need for clinicians practicing in a hospital setting to possess adequate knowledge of ILD incidence, the skills to perform a differential diagnosis, and provide adequate management and treatment that is effective upon a patient’s return to the community or long-term care setting. This program aims to address these important clinical needs.

Intended Audience

This educational initiative has been designed for pulmonologists, internal medicine physicians, and physicians in training involved in the care of patients with ILD.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Outline a multidisciplinary approach for the differential diagnosis of ILD
  • Discuss the latest evidence-based guidelines for idiopathic pulmonary fibrosis (IPF) and review strategies for individualized management of patients with ILD
  • Describe strategies for ensuring adequate communication between clinicians and patients over the course of ILD management

Conflict Of Interest Disclosure Policy

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Lisa H. Lancaster, MD
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Vanderbilt University Medical Center
Nashville, TN

Dr. Lancaster discloses the following:
Consultant: Boehringer Ingelheim Pharmaceuticals, Inc., Genentech
Contracted Research: Boehringer Ingelheim Pharmaceuticals, Inc., Celgene, Genentech, Global Brand Therapeutics

Steven D. Nathan, MD
Medical Director
Lung Transplant Program
Advanced Lung Disease Program
Inova Fairfax Hospital
Fairfax, VA

Dr. Nathan discloses the following:
Consultant: Bayer Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., Roche-Genentech
Contracted Research: Boehringer Ingelheim Pharmaceuticals, Inc., Roche-Genentech

Accredited Provider Disclosure

Patima Tanapat, PhD, has no real or apparent conflicts of interest to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation Statement

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc., do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc., and Boehringer Ingelheim Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.


There are no fees for participating and receiving CME credit for this activity. During the period of October 6, 2017 through October 6, 2018, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 100%.

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or

If you have any questions relating to your certificate or other issues with this activity, please contact

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue